Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
25
01
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
25
5
2022
Statut:
ppublish
Résumé
To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis. Postmenopausal patients with primary osteoporosis. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements. This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.
Identifiants
pubmed: 35594133
doi: 10.1097/AOG.0000000000004730
pii: 00006250-202204000-00036
doi:
Substances chimiques
Calcium, Dietary
0
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-717Investigateurs
JoAnn V Pinkerton
(JV)
David Chelmow
(D)
Catherine T Witkop
(CT)
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 2019;171:37–50. doi: 10.7326/M19-0533
doi: 10.7326/M19-0533
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465–75. doi: 10.1359/jbmr.061113
doi: 10.1359/jbmr.061113
Osteoporosis prevention, screening, and diagnosis. Clinical Practice Guideline No. 1. American College of Obstetricians and Gynecologists. Obstet Gynecol 2021;138:494–506. doi: 10.1097/AOG.0000000000004514
doi: 10.1097/AOG.0000000000004514
Clinical practice guideline methodology: methodology. American College of Obstetricians and Gynecologists. Obstet Gynecol 2021;138:518–22. doi: 10.1097/AOG.0000000000004519
doi: 10.1097/AOG.0000000000004519
United Nations Development Programme. Human Development Reports: Human Development Index (HDI). Accessed December 7, 2021. http://hdr.undp.org/en/content/human-development-index-hdi
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6. doi: 10.1136/bmj.39489.470347.AD
doi: 10.1136/bmj.39489.470347.AD
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94. doi: 10.1016/j.jclinepi.2010.04.026
doi: 10.1016/j.jclinepi.2010.04.026
Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol 2015;68:597–600. doi: 10.1016/j.jclinepi.2014.12.011
doi: 10.1016/j.jclinepi.2014.12.011
U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Accessed December 7, 2021. https://www.ncbi.nlm.nih.gov/books/NBK45513
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–3. doi: 10.1001/jama.285.3.320
doi: 10.1001/jama.285.3.320
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104:1595–622. doi: 10.1210/jc.2019-00221
doi: 10.1210/jc.2019-00221
Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052–7. doi: 10.1001/archinte.163.17.2052
doi: 10.1001/archinte.163.17.2052
Hamrick I, Cao Q, Agbafe-Mosley D, Cummings DM. Osteoporosis healthcare disparities in postmenopausal women. J Womens Health (Larchmt) 2012;21:1232–6. doi: 10.1089/jwh.2012.3812
doi: 10.1089/jwh.2012.3812
Curtis JR, McClure LA, Delzell E, Howard VJ, Orwoll E, Saag KG, et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009;24:956–62. doi: 10.1007/s11606-009-1031-8
doi: 10.1007/s11606-009-1031-8
Sattari M, Cauley JA, Garvan C, Johnson KC, LaMonte MJ, Li W, et al. Osteoporosis in the Women's Health Initiative: another treatment gap? Am J Med 2017;130:937–48. doi: 10.1016/j.amjmed.2017.02.042
doi: 10.1016/j.amjmed.2017.02.042
Wright NC, Chen L, Saag KG, Brown CJ, Shikany JM, Curtis JR. Racial disparities exist in outcomes after major fragility fractures. J Am Geriatr Soc 2020;68:1803–10. doi: 10.1111/jgs.16455
doi: 10.1111/jgs.16455
Importance of social determinants of health and cultural awareness in the delivery of reproductive health care. ACOG Committee Opinion No. 729. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e43–8. doi: 10.1097/AOG.0000000000002459
doi: 10.1097/AOG.0000000000002459
Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in health care. National Academies Press; 2003.
Williams DR, Mohammed SA. Racism and health I: pathways and scientific evidence. Am Behav Sci 2013;57:10.1177/0002764213487340. doi: 10.1177/0002764213487340
doi: 10.1177/0002764213487340
Williams DR, Lawrence JA, Davis BA. Racism and health: evidence and needed research. Annu Rev Public Health 2019;40:105–25. doi: 10.1146/annurev-publhealth-040218-043750
doi: 10.1146/annurev-publhealth-040218-043750
Hamrick I, Steinweg KK, Cummings DM, Whetstone LM. Health care disparities in postmenopausal women referred for DXA screening. Fam Med 2006;38:265–9.
Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB. Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med 2007;22:1239–45. doi: 10.1007/s11606-007-0217-1
doi: 10.1007/s11606-007-0217-1
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. In: WHO Technical Report Series 843. Accessed December 7, 2021. https://apps.who.int/iris/bitstream/handle/10665/39142/WHO_TRS_843_eng.pdf
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 2020;26(suppl 1):1–46. doi: 10.4158/GL-2020-0524SUPPL
doi: 10.4158/GL-2020-0524SUPPL
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation [published erratum appears in Osteoporos Int 2015;26:2045–7]. Osteoporos Int 2014;25:2359–81. doi: 10.1007/s00198-014-2794-2
doi: 10.1007/s00198-014-2794-2
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2013;11(suppl 3):S1–50. doi: 10.6004/jnccn.2013.0215
doi: 10.6004/jnccn.2013.0215
Villa P, Lassandro AP, Amar ID, Vacca L, Moruzzi MC, Ferrandina G, et al. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. Menopause 2016;23:33–9. doi: 10.1097/GME.0000000000000515
doi: 10.1097/GME.0000000000000515
Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat 2020;179:275–85. doi: 10.1007/s10549-019-05464-w
doi: 10.1007/s10549-019-05464-w
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 2019;37:2916–46. doi: 10.1200/JCO.19.01696
doi: 10.1200/JCO.19.01696
Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;319:2532–51. doi: 10.1001/jama.2018.6537
doi: 10.1001/jama.2018.6537
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. US Preventive Services Task Force. JAMA 2018;319:2521–31. doi: 10.1001/jama.2018.7498
doi: 10.1001/jama.2018.7498
Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis [published erratum appears in J Clin Endocrinol Metab 2021;106:e1494]. J Clin Endocrinol Metab 2019;104:1623–30. doi: 10.1210/jc.2019-00192
doi: 10.1210/jc.2019-00192
Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, et al. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 2020;130:115081. doi: 10.1016/j.bone.2019.115081
doi: 10.1016/j.bone.2019.115081
Yang L, Kang N, Yang JC, Su QJ, Liu YZ, Guan L, et al. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:2640–68. doi: 10.26355/eurrev_201903_17414
doi: 10.26355/eurrev_201903_17414
Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 2020;105:dgaa048. doi: 10.1210/clinem/dgaa048
doi: 10.1210/clinem/dgaa048
Yuan F, Peng W, Yang C, Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg 2019;66:1–11. doi: 10.1016/j.ijsu.2019.03.004
doi: 10.1016/j.ijsu.2019.03.004
Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, et al. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Maturitas 2019;129:12–22. doi: 10.1016/j.maturitas.2019.08.003
doi: 10.1016/j.maturitas.2019.08.003
Barrionuevo P, Gionfriddo MR, Castaneda-Guarderas A, Zeballos-Palacios C, Bora P, Mohammed K, et al. Women's values and preferences regarding osteoporosis treatments: a systematic review. J Clin Endocrinol Metab 2019;104:1631–6. doi: 10.1210/jc.2019-00193
doi: 10.1210/jc.2019-00193
Albert SG, Reddy S. Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis. Endocr Pract 2017;23:841–56. doi: 10.4158/EP161678.RA
doi: 10.4158/EP161678.RA
Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 2014;58:126–35. doi: 10.1016/j.bone.2013.09.023
doi: 10.1016/j.bone.2013.09.023
Wu CH, Hung WC, Chang IL, Tsai TT, Chang YF, McCloskey EV, et al. Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: systemic review and meta-analysis. Bone Rep 2020;13:100729. doi: 10.1016/j.bonr.2020.100729
doi: 10.1016/j.bonr.2020.100729
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018;379:2407–16. doi: 10.1056/NEJMoa1808082
doi: 10.1056/NEJMoa1808082
Siris ES, Simon JA, Barton IP, McClung MR, Grauer A. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 2008;19:681–6. doi: 10.1007/s00198-007-0493-y
doi: 10.1007/s00198-007-0493-y
Fardellone P, Lello S, Cano A, de Sá Moreira E, Watanabe de Oliveira R, Julian GS, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 2019;41:1576–88. doi: 10.1016/j.clinthera.2019.05.001
doi: 10.1016/j.clinthera.2019.05.001
Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010;21:145–55. doi: 10.1007/s00198-009-0930-1
doi: 10.1007/s00198-009-0930-1
Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published erratum appears in J Bone Miner Res 2016;31:1910]. J Bone Miner Res 2016;31:16–35. doi: 10.1002/jbmr.2708
doi: 10.1002/jbmr.2708
Ward RJ, Roberts CC, Bencardino JT, Arnold E, Baccei SJ, Cassidy RC, et al. ACR Appropriateness Criteria(®): osteoporosis and bone mineral density. Expert Panel on Musculoskeletal Imaging. J Am Coll Radiol 2017;14:S189–202. doi: 10.1016/j.jacr.2017.02.018
doi: 10.1016/j.jacr.2017.02.018
Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig 2019;40:/j/hmbci.2019.40.issue-0021. doi: 10.1515/hmbci-2019-0021
doi: 10.1515/hmbci-2019-0021
National Library of Medicine. Alendronate sodium tablet. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c23fb7fe-c6b9-4f77-bde7-992222b589d3
National Library of Medicine. Zoledronic acid injection, solution. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c79ff9c-a6f4-405d-b19c-7e473a61dedc
Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020;383:743–53. doi: 10.1056/NEJMoa1916525
doi: 10.1056/NEJMoa1916525
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. FLEX Research Group. JAMA 2006;296:2927–38. doi: 10.1001/jama.296.24.2927
doi: 10.1001/jama.296.24.2927
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [published erratum appears in J Bone Miner Res 2012;27:2612]. J Bone Miner Res 2012;27:243–54. doi: 10.1002/jbmr.1494
doi: 10.1002/jbmr.1494
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513–23. doi: 10.1016/S2213-8587(17)30138-9
doi: 10.1016/S2213-8587(17)30138-9
Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J 2019;60:364–78. doi: 10.11622/smedj.2019028
doi: 10.11622/smedj.2019028
National Library of Medicine. Denosumab injection. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88
Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab 2019;104:2443–52. doi: 10.1210/jc.2018-01965
doi: 10.1210/jc.2018-01965
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018;33:190–8. doi: 10.1002/jbmr.3337
doi: 10.1002/jbmr.3337
National Library of Medicine. Raloxifene hydrochloride tablet. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9
Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514–24. doi: 10.1359/JBMR.050509
doi: 10.1359/JBMR.050509
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;322:868–86. doi: 10.1001/jama.2019.5780
doi: 10.1001/jama.2019.5780
Constantine GD, Kagan R, Miller PD. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. Menopause 2016;23:638–44. doi: 10.1097/GME.0000000000000619
doi: 10.1097/GME.0000000000000619
Management of menopausal symptoms. Practice Bulletin No. 141 [published errata appear in Obstet Gynecol 2018;131:604; Obstet Gynecol 2016;127:166]. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:202–16. doi: 10.1097/01.AOG.0000441353.20693.78
doi: 10.1097/01.AOG.0000441353.20693.78
Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Women's Health Initiative Investigators. JAMA 2003;290:1729–38. doi: 10.1001/jama.290.13.1729
doi: 10.1001/jama.290.13.1729
Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. Women's Health Initiative Investigators. J Bone Miner Res 2006;21:817–28. doi: 10.1359/jbmr.060312
doi: 10.1359/jbmr.060312
Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Early Postmenopausal Intervention Cohort Study Group. Menopause 2004;11:622–30. doi: 10.1097/01.gme.0000123641.76105.b5
doi: 10.1097/01.gme.0000123641.76105.b5
National Library of Medicine. DUAVEE-conjugated estrogens/bazedoxifene tablet, film coated. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb
Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52. doi: 10.1016/j.fertnstert.2009.02.093
doi: 10.1016/j.fertnstert.2009.02.093
Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. SMART-5 Investigators. J Clin Endocrinol Metab 2014;99: E189–98. doi: 10.1210/jc.2013-1707
doi: 10.1210/jc.2013-1707
National Library of Medicine. Calcitonin salmon spray, metered. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82eb602-12e1-692b-d660-f8d5b5736b54&audience=professional
Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267–76. doi: 10.1016/s0002-9343(00)00490-3
doi: 10.1016/s0002-9343(00)00490-3
U.S. Food and Drug Administration. Questions and answers: changes to the indicated population for Miacalcin (calcitonin-salmon). Accessed December 7, 2021. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-changes-indicated-population-miacalcin-calcitonin-salmon
National Library of Medicine. Teriparatide injection, solution. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b007339-dd0d-f019-5e0a-9b1b0f75011c
National Library of Medicine. Abaloparatide injection, solution. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8
Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone 2019;120:137–40. doi: 10.1016/j.bone.2018.10.015
doi: 10.1016/j.bone.2018.10.015
McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos 2019;14:15–7. doi: 10.1007/s11657-019-0564-7
doi: 10.1007/s11657-019-0564-7
Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 2018;103:2949–57. doi: 10.1210/jc.2018-00163
doi: 10.1210/jc.2018-00163
National Library of Medicine. Romosozumab-aqqg injection, solution. Drug label information. Accessed December 7, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=471baba2-7154-4488-9891-0db2f46791e
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532–43. doi: 10.1056/NEJMoa1607948
doi: 10.1056/NEJMoa1607948
Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, et al. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 2018;21:189–95. doi: 10.1080/13697137.2018.1433655
doi: 10.1080/13697137.2018.1433655
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377:1417–27. doi: 10.1056/NEJMoa1708322
doi: 10.1056/NEJMoa1708322
McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 2018;33:1397–406. doi: 10.1002/jbmr.3452
doi: 10.1002/jbmr.3452
Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 2019;30:2437–48. doi: 10.1007/s00198-019-05146-9
doi: 10.1007/s00198-019-05146-9
Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117–23. doi: 10.1210/jc.2003-030501
doi: 10.1210/jc.2003-030501
Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJ. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 2018;29:2623–37. doi: 10.1007/s00198-018-4759-3
doi: 10.1007/s00198-018-4759-3
Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) [published errata appear in Osteoporos Int 2020;31:209; Osteoporos Int 2020;31:801]. Osteoporos Int 2019;30:3–44. doi: 10.1007/s00198-018-4704-5
doi: 10.1007/s00198-018-4704-5
Institute of Medicine. Dietary reference intakes for calcium and vitamin D. National Academies Press; 2011.
Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation [published erratum appears in Osteoporos Int 2016;27:2643–6]. Osteoporos Int 2016;27:367–76. doi: 10.1007/s00198-015-3386-5
doi: 10.1007/s00198-015-3386-5
Weaver CM, Dawson-Hughes B, Lappe JM, Wallace TC. Erratum and additional analyses re: calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 2016;27:2643–6. doi: 10.1007/s00198-016-3699-z
doi: 10.1007/s00198-016-3699-z
Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J, et al. Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1917789. doi: 10.1001/jamanetworkopen.2019.17789
doi: 10.1001/jamanetworkopen.2019.17789
Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M, et al. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;319:1600–12. doi: 10.1001/jama.2017.21640
doi: 10.1001/jama.2017.21640
North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011;18:732–53. doi: 10.1097/gme.0b013e31821fc8e0
doi: 10.1097/gme.0b013e31821fc8e0
Abdi F, Alimoradi Z, Haqi P, Mahdizad F. Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials. Climacteric 2016;19:535–45. doi: 10.1080/13697137.2016.1238451
doi: 10.1080/13697137.2016.1238451
Lambert MN, Hu LM, Jeppesen PB. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women. Am J Clin Nutr 2017;106:801–11. doi: 10.3945/ajcn.116.151464
doi: 10.3945/ajcn.116.151464
Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. Menopause 2013;20:1207–15. doi: 10.1097/GME.0b013e3182896ae5
doi: 10.1097/GME.0b013e3182896ae5
Dostal AM, Arikawa A, Espejo L, Kurzer MS. Long-term supplementation of green tea extract does not modify adiposity or bone mineral density in a randomized trial of overweight and obese postmenopausal women. J Nutr 2016;146:256–64. doi: 10.3945/jn.115.219238
doi: 10.3945/jn.115.219238
Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Osteoporos Int 2012;23:1317–27. doi: 10.1007/s00198-011-1577-2
doi: 10.1007/s00198-011-1577-2
Koutsofta I, Mamais I, Chrysostomou S. The effect of protein diets in postmenopausal women with osteoporosis: systematic review of randomized controlled trials. J Women Aging 2019;31:117–39. doi: 10.1080/08952841.2018.1418822
doi: 10.1080/08952841.2018.1418822
König D, Oesser S, Scharla S, Zdzieblik D, Gollhofer A. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women–a randomized controlled study. Nutrients 2018;10:97. doi: 10.3390/nu10010097
doi: 10.3390/nu10010097
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 2021;28:973–97. doi: 10.1097/GME.0000000000001831
doi: 10.1097/GME.0000000000001831
Bell K, Strand H, Inder WJ. Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review. Arch Osteoporos 2014;9:167. doi: 10.1007/s11657-013-0167-7
doi: 10.1007/s11657-013-0167-7